Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT VI on acquisition of Atos Medical
Mandate

Vinge advises EQT VI on acquisition of Atos Medical

July 22, 2011

Vinge is advising funds managed by EQT VI Limited in connection with the acquisition of Atos Medical from funds managed by Nordic Capital V Limited (94.6%) and board directors and employees (5.4%). Atos supplies products to the ear, nose and throat (“ENT”) medical segment and is the market leader in voice prosthesis. The acquisition is subject to customary conditions.

The Vinge team included partners Christina Kokko and Johan Göthberg and associates Malin Helgesen, Peter Sundgren, Paul Dali and Anna-Sofia Nilsson Prevell (M&A), partner Maria-Pia Hope and associates Albert Wållgren and Andreas Malmberg (banking & finance), and partner Marcus Glader and associate Peter Alstergren (EU & competition).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026